Redeye returns with a more in-depth take on OssDsign’s Q1 report.
Nanexa continues to strengthen the foundation for the upcoming Phase Ib/II study in the NEX-22 proje...
Redeye comments on Combinedx’s Q1 report, showing solid profitability yet somewhat lower sales than ...
Redeye updates its estimates following Freemelt’s Q1 report, which came in lower than expected in te...
Redeye provides an update following Optomed’s Q1 2025 report.
Redeye updates its estimates and fair value range following CTEK’s Q1 results, which exceeded our ex...
Redeye provides an update on Scandinavian ChemoTech following the Q1 2025 report.
Redeye comments on the outcome of AcouSort’s rights issue.
NoHo Partners' Q1 2025 results missed Vara Research expectations on several items, but we argue that...
Redeye retains its view of Hanza following a Q1 report showing a relatively solid performance in a s...
Impressive margin lift in both segments, EBITA +6% vs.
Soft Q1 sales of SEK 2.9m on no machine deliveries, but 6 orders Share issue readies balance sheet f...
Delivery on both sales and gross margin above expectations EBIT revised up by 11-22% for '25e-'27e F...
Redeye provides its comment on Mendus’ Q1 2025 report.
Redeye comments on Invisio’s Q1-results which came in below our forecast with lower activity than ex...
EBITA SEK 271m (+3% vs. ABG, +6% vs. IR cons) We expect cons EBITA upgrades of 3-4% for '25e 15-13x ...
Redeye is revising near-term forecasts and valuation, following a weak Q1 and current market headwin...
Embracer becomes a shareholder in Starbreeze through a directed new share issue of 9% of the total n...
Redeye comments on Bredband2’s Q1 report where accelerated growth efforts resulted in a strong custo...
Sales +2% vs. ABGSCe, but EBITA 17% below Good customer intake, but margins weighted by investments ...
